| GTO ID | GTC1680 |
| Trial ID | NCT02988258 |
| Disease | Hematologic Cancer |
| Altered gene | CMV |
| Therapeutic/Target gene | Target gene |
| Therapy | TCR-T cell |
| Treatment | CMV TCR-T cells |
| HLA | HLA-A*02:01 |
| Phase | Phase1 |
| Recruitment status | Suspended |
| Title | CMV TCR Gene Therapy: A Phase I Safety, Toxicity and Feasibility Study of Adoptive Immunotherapy With CMV TCR-transduced Donor-derived T Cells for Recipients of Allogeneic Haematopoietic Stem Cell Transplantation |
| Year | 2012 |
| Country | United Kingdom |
| Company sponsor | University College, London |
| Other ID(s) | UCL 08/0214|2008-006649-18|G0701703|08/0214 |
| Vector information | |||
|
|||
| Cohort1: dose level 1 | |||||||||||
|
|||||||||||
| Cohort2: dose level 2 | |||||||||||
|
|||||||||||
| Cohort3: dose level 3 | |||||||||||
|
|||||||||||